Type of study in modified release formu­lation EMEA [Regulatives / Guidelines]

posted by kumarnaidu – Mumbai, India, 2014-11-27 13:53 (3857 d 07:30 ago) – Posting: # 13930
Views: 15,572

❝ The guideline allows widening for Ctau,ss as for highly variable drugs. Did you go for that in the protocol?


Ok thanks for the reply. But I think for applying widening criteria we need to show CV>30% for reference product and the study should be reference replicate (3way or 4way).
Can we use Pre-dose concentration and Ctau of steady state to show variability?:confused:

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,676 registered users;
26 visitors (0 registered, 26 guests [including 9 identified bots]).
Forum time: 22:23 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5